Details
Stereochemistry | ACHIRAL |
Molecular Formula | 3Cl.Ga |
Molecular Weight | 173.287 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[67Ga+3]
InChI
InChIKey=UPWPDUACHOATKO-MPZFSRPWSA-K
InChI=1S/3ClH.Ga/h3*1H;/q;;;+3/p-3/i;;;1-3
Molecular Formula | Ga |
Molecular Weight | 66.9282 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:35:36 GMT 2023
by
admin
on
Fri Dec 15 18:35:36 GMT 2023
|
Record UNII |
A04B19O2B0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB14550
Created by
admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
|
PRIMARY | |||
|
A04B19O2B0
Created by
admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
|
PRIMARY | |||
|
314639
Created by
admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
73415785
Created by
admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
|
PRIMARY | |||
|
A04B19O2B0
Created by
admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |